RNA - NASDAQ

Atrium Therapeutics, Inc.

RNA·NASDAQ

$12.17

-1.3%

HealthcareBiotechnology

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$208.18M

EPS-4.4800

P/E Ratio-2.72

Earnings Date09/02/2026

rna

Other Current Assets

Last Annual Value

1.31M

3-Year CAGR

5-Year CAGR

10-Year CAGR

24%

Adjust for Inflation

Atrium Therapeutics, Inc. Competitors Analysis of Other Current Assets

RNA · NASDAQ

Company	Other Current Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Atrium Therapeutics, Inc. NASDAQ:RNA	1.31M	N/A	N/A	N/A
Caris Life Sciences, Inc. NASDAQ:CAI	85.57M	158.3%	N/A	N/A
Moderna, Inc. NASDAQ:MRNA	408.00M	66.7%	73.4%	N/A
Nuvalent, Inc. NASDAQ:NUVL	0.00	N/A	N/A	N/A
Jazz Pharmaceuticals plc NASDAQ:JAZZ	476.44M	14.1%	13.5%	32.2%
Rhythm Pharmaceuticals, Inc. NASDAQ:RYTM	9.97M	14.3%	20.1%	46.7%
Cytokinetics, Incorporated NASDAQ:CYTK	34.75M	N/A	N/A	N/A
Bio-Techne Corporation NASDAQ:TECH	49.79M	22.5%	24.1%	20.7%
Madrigal Pharmaceuticals, Inc. NASDAQ:MDGL	52.89M	156.1%	N/A	N/A

Atrium Therapeutics, Inc. Fair Value Envelope

RNA · NASDAQ

Our analysis suggests that RNA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $12.17, this represents a potential HIDDEN relative to our calculated worth for Atrium Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $12.17

Related Guides

Blog Categories

Continue your RNA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.